{"page_content": "8Strategy and Analysis\nOrganizational ProfileNumber Disclosure Reported Response\n1.1 Statement from CEO environment.amgen.com (Leadership Message)\nNumber Disclosure Reported Response\n2.1 Name of organization Amgen\n2.2 Primary brands, products, and/or services www.amgen.com (Product websites)\n2.3 Operational structure www.amgen.com (Amgen Fact Sheet)\n2.4 Location of headquarters Thousand Oaks, CA\n2.5 Countries of operation www.amgen.com (Amgen Fact Sheet)\n2.6 Nature of ownership www.amgen.com (Amgen Fact Sheet)\n2.7 Markets served www.amgen.com (Amgen Fact Sheet)\n2.8 Scale of the reporting organization www.amgen.com (Amgen Fact Sheet)\n2.9 Significant changes during the reporting period None\n2.10 Awards Awards and RecognitionAmgen reports in alignment with the Global Reporting Initiative (GRI) G3.1 guidelines. The GRI guidelines offer a useful framework to help companies standardize their \nsustainability reporting. We are reporting on our 2014 performance at a self-declared application level C+.\nThe scope of the environmental data in our report includes 15 manufacturing, research and development, and distribution facilities in North America and Europe. These facilities \nrepresent approximately 94 percent of our operations, based on the square footage of our facilities. The remaining square footage primarily includes administrative offices.\nOur 2014 environmental data for this report have undergone limited assurance by Bureau Veritas.In 2013, Amgen acquired Onyx Pharmaceuticals. No data will be included for this facility in this report, as we are still working through the integration process.\nThe index summarizes Amgen\u2019s disclosures in relation to the GRI G3.1 indicators.GRI Index\nReport Parameters\nNumber Disclosure Reported Response\n3.1 Reporting period January 1, 2014, to December 31, 2014\n3.2 Date of most recent report May 2014\n3.3 Reporting cycle Annual\n3.4 Contact point esfeedback@amgen.com\n3.5 Process for defining report contentenvironment.amgen.com (Amgen\u2019s Environmental Sustainability Plan)\nenvironment.amgen.com (Stakeholder Engagement) \n3.6 Boundary of the reportAmgen facilities within the scope of this report are as follows:\nUnited States: Thousand Oaks, California; Cambridge, \nMassachusetts; Woburn, Massachusetts; Greenwich, Rhode Island; Louisville, Kentucky; South San Francisco, California; Boulder and Longmont, Colorado; Juncos, Puerto Rico; Seattle and Bothell, Washington; Field Sales US Fleet\nCanada: Burnaby, British Columbia\nEurope: Breda, Netherlands; Uxbridge, Abingdon, and Cambridge, \nUnited Kingdom; Dun Laoghaire, Ireland\nReported PartialNumber Disclosure Reported Response\n3.7 Limitations on the scope and boundary of the reportItems that are out of scope for this report include global sales and administrative offices with minimal environmental impact; outsourced activities, such as contract manufacturers; Onyx Pharmaceuticals,  which was acquired in 2013; companies acquired in 2012, including Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals; and Amgen\u2019s facility in S\u00e3o Paulo, Brazil, acquired in 2011.\n3.8 Basis for reporting\nThe in-scope facilities listed in indicator 3.6 represent our 15 manufacturing, research and development, and distribution facilities in North America, Europe, and Puerto Rico. These facilities represent 94 percent of our operations, based on the square footage of our facilities. The remaining square footage primarily includes administrative offices. We do not include environmental data from outsourced activities in this report.\n3.9 Data measurement techniques and basis of calculations and assumptions\nenvironment.amgen.com (Summary of Data Notes)\n3.10 Explanation of the effect of any restatements No restatements\n3.11 Significant changes from previous reporting periods None\n3.12 GRI content index table environment.amgen.com (GRI Index)\nNumber Disclosure Reported Response\n4.1 Governance structure including committeesenvironment.amgen.com (Governance) \nwww.amgen.com (Corporate Governance)\n4.2 Indicate whether the chair of the highest governance body is also an executive officerRobert Bradway is both CEO and Chairman of the Board. For more \ninformation on Amgen\u2019s Board, see amgen.com (Corporate Governance) \n4.3 Unitary board structure www.amgen.com (Corporate Governance)\n4.4Mechanisms for shareholders and employees to provide recommendations/direction to highest governance boardwww.amgen.com (Corporate Governance)\n4.14 List of stakeholder groups engaged by the organization environment.amgen.com (Stakeholder Engagement)\n4.15 Basis for identification and selection of stakeholders with whom to engage environment.amgen.com (Stakeholder Engagement)\nNumber Disclosure Reported Response\nEC1 Economic Performance: Direct economic value generated and distributedenvironment.amgen.com (Summary of Data and Data Notes)\nwww.amgen.com (2014 Annual Report and Financial Summary)\nEC2Economic Performance: Financial implications and other risks and opportunities due to climate changeWe\u2019re actively working to conserve energy and reduce greenhouse gas emissions that result from our operations. We have also considered potential risks to our business associated with climate change such as extreme weather events and increasing regulation. Financial impact is considered as part of our risk management processes. Having plans in place to mitigate these risks increases the overall sustainability of the business.\nEC9Indirect Economic Impacts: Understanding and describing significant indirect economic impacts, including the extent of impacts\nwww.amgen.com (AmgenAssist)", "metadata": {"source": "NASDAQ_AMGN_2014.pdf", "page": 7, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}